Supplemental Materials: Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, phase 2b trial (IASOS)_JAAD

Published: 8 November 2023| Version 2 | DOI: 10.17632/dkbxwxmtfv.2
Contributors:
Richard Warren, Lars French

Description

Supplemental information for the manuscript in the Journal of the American Academy of Dermatology (JAAD): "Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, phase 2b trial (IASOS)"

Files

Categories

Psoriasis, Phosphodiesterase Inhibitor, Efficacy Assessment, Efficacy Study

Licence